GPCR · Structure Therapeutics Inc.
$49.12
-1.68 (-3.31%)
At close · Jul 24
Market Cap
$10.47B
Shares
213.22M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$141.2M
-15.2%
FY2025
Diluted EPS
-$0.80
-2.6%
FY2025
Operating Cash Flow
-$222.2M
-90.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| $248.9M | $225.26M | $108.81M | $70.1M | $36.19M | |
| $70.98M | $61.55M | $49.41M | $32.67M | $16.37M | |
| $209.63M | $176.56M | $158.23M | $102.78M | $52.56M | |
| -$209.63M | -$176.56M | -$158.23M | -$102.78M | -$52.56M | |
| -$169.73M | -$140.69M | -$122.22M | -$89.38M | -$51.3M | |
| $607K | $515K | $310K | $236K | $17K | |
| -$170.34M | -$141.2M | -$122.53M | -$89.62M | -$51.32M | |
| -$110.55M | — | — | -$89.62M | -$52.84M | |
| -$173.35M | -$141.06M | -$122.13M | -$88.99M | -$51.43M | |
| USD/shares | — | -$0.80 | -$0.78 | -$0.81 | -$5.51 |
| USD/shares | — | -$0.80 | -$0.78 | -$0.81 | -$5.51 |
| shares | — | 177.6M | 157.92M | 110.2M | 9.58M |
| shares | — | 177.6M | 157.92M | 110.2M | 9.58M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.41×
EV/EBIT
—
Biotechnology median 26.60×
P/E (TTM)
—
Biotechnology median 7.07×
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Single Reportable Segment | -$176,560,000 | -$158,228,000 | -$102,775,000 |
Key facts
CIK
1888886
CUSIP
86366E106
13F (30d)
20 filings
20 filers
Visit website
Investor relations